LOXO stock: buy or sell?
February 14th, 2019
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States.
Should I buy LOXO stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
These 2 buy setups work for Loxo Oncology stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Loxo Oncology stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we detected 3 ratings published for LOXO stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
LOXO stock analysis
Loxo Oncology remained constant -0.03% to $234.66 after yesterday all time highs.
After yesterday all time highs, Loxo Oncology remained constant to $234.66. Since last January when LOXO stock price broke up the SMA200d line, it gained $94.79 (67.77%). Since SMA50d and SMA100d crossed up on January, LOXO price climbed $1.16 per share (0.50%). On February, LOXO hit new all time highs, pushing higher previous ATH of $234.78 recorded on February. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Shares of Loxo Oncology ended this week at $234.66 after topping to a new all time high ($234.93) and remained stable a neutral 0.10%. Early January LOXO rocketed an astounding 39.84% in just one week.
Since SMA20d and SMA40w crossed up late January, LOXO price climbed $0.88 per share (0.38%). Since price and SMA40w lines crossed up early January, LOXO climbed $94.79 (67.77%).
LOXO stock price history
LOXO IPO was on January 4th, 2018 at $84.79 per share1. Since then, LOXO stock surged a 176.80%, with an average of 176.80% per year. If you had invested $1,000 in LOXO stock in 2018, it would worth $1,768.00 today.
1: Adjusted price after possible price splits or reverse-splits.
LOXO stock historical price chart
LOXO stock reached all-time highs on February with a price of $234.93.
LOXO stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' LOXO stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price prediction for Loxo Oncology stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareLoxo Oncology will present its financial report on February. Analysts expect an Earnings per Share (EPS) ratio of $-0.87. On November, Loxo Oncology presented its financial report, posting an extraordinary growth for the Earnings per Share (EPS). Experts expected $-0.65 per share, but Loxo Oncology posted $-0.89.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2017, Loxo Oncology annual revenues to $21.30 million dollars from marked in . When comparing 2017 vs , , profit margin (that is, the net income divided by revenues) a to -698.95%. Loxo Oncology presents anual results in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Loxo Oncology TTM sales up to September 2018 were $144.80 and income $-62.98 M dollars. When comparing this TTM figures with the last reported annuality, we can review Loxo Oncology business evolution since December 2017: Annual revenues up to September, compared to lastest yearly report, boosted a dazzling 579.81%. Aligned with this, profit margin (net income/sales) climbed at -698.95%.
|2017||$21 M||-||$-148.88 M-698.9%||-|
|TTM||$145 M||579.81%||$-62.98 M-43.5%||-57.70%|
Quarterly financial resultsLoxo Oncology reported $42.47 million in revenues for 2018-Q3, a -0.31% less compared to previous quarter. Reported quarter income marked $-27.06 M with a profit margin of -63.72%. Profit margin plummed a -36.20% compared to previous quarter when profit margin was -27.53%. When comparing turnover to same quarter last year, Loxo Oncology sales marked an astounding increase and rocketed a inf%.
|2017-Q4||$21 M||-||$-20.63 M-96.8%||-|
|2018-Q1||$38 M||80.42%||$-3.56 M-9.3%||-82.75%|
|2018-Q2||$43 M||10.86%||$-11.73 M-27.5%||229.57%|
|2018-Q3||$42 M||-0.31%||$-27.06 M-63.7%||130.80%|
Loxo Oncology ownershipWhen you are planning to invest in a company, it's worth to review its ownership structure.
Loxo Oncology shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Thursday, February 14th, 2019|
|Day range||$234.66 - $234.88|
|Average true range||$0.37|
|50d mov avg||$190.85|
|100d mov avg||$175.26|
|200d mov avg||$170.49|
Loxo Oncology performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Loxo Oncology performance to :